Search

Author/Creator Garassino, M.C.

1. 122MO Cemiplimab (cemi) + platinum doublet chemotherapy (chemo) + ipilimumab (ipi) for first-line treatment of advanced non-small cell lung cancer (NSCLC): EMPOWER-Lung 3 part I. (December 2022)

Authors:
Baramidze, A.; Gogishvili, M.; Melkadze, T.; Giorgadze, D.; Penkov, K.D.; Makharadze, T.; Kalinka, E.; Nechaeva, M.; Laktionov, K.; Gessner, C.; Moreno Jaime, B.; Passalacqua, R.; Garassino, M.C.; Li, S.; Pouliot, J-F.; McGuire, K.; Quek, R.G.; Kaul, M.; Gullo, G.; Rietschel, P.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 25P Platinum-based chemotherapy (PCT) addition to first-line PD-1/PD-L1 inhibitors (ICI) prevent hyperprogressive disease (HPD) in non-small cell lung cancer (NSCLC) patients (pts) by reducing circulating immature neutrophils. (December 2022)

Authors:
Ferrara, R.; Lo Russo, G.; Ciniselli, C.M.; Bassani, B.; Calareso, G.; Duroni, V.; Di Gregorio, S.; Proto, C.; Prelaj, A.; De Toma, A.; Occhipinti, M.; Brambilla, M.; Manglaviti, S.; Mazzeo, L.; Ganzinelli, M.; De Braud, F.G.M.; Garassino, M.C.; Colombo, M.P.; Verderio, P.; Sangaletti, S.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 58O Real-world overall survival (OS) with durvalumab (D) after chemoradiotherapy (CRT) in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC): Interim analysis from the PACIFIC-R study. (December 2022)

Authors:
Girard, N.; Christoph, D.C.C.; Garassino, M.C.; McDonald, F.; Mornex, F.; Field, J.K.; Fietkau, R.; Garrido Lopez, P.; Haakensen, V.D.; Siva, S.; van den Heuvel, M.; Bar, J.; Chouaid, C.; Vercauter, P.; Chander, P.; Licour, M.; Anand, S.; de Lima, A.R.M.D.; Filippi, A.R.R.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. (May 2019)

Authors:
Proto, C.; Ferrara, R.; Signorelli, D.; Lo Russo, G.; Galli, G.; Imbimbo, M.; Prelaj, A.; Zilembo, N.; Ganzinelli, M.; Pallavicini, L.M.; De Simone, I.; Colombo, M.P.; Sica, A.; Torri, V.; Garassino, M.C.
Journal:
Cancer treatment reviews
Issue:
Volume 75(2019)
Page Start:
39
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. LBA4 Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. (December 2022)

Authors:
Jänne, P.A.; Smit, E.F.; de Marinis, F.; Laskin, J.; Gomez, M. Domine; Gadgeel, S.; Garassino, M.C.; Lu, S.; Spira, A.S.; Kang, V.; Roshan, S.; Yan, X.; Felip, E.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗